RIPK1 and neoplasm: We observed that the key molecules RIPK1 and RIPK3 are significantly upregulated during TCR restimulation, and blocking necroptotic cell death pathway using the pharmacological inhibitor rescues effector T cells from cell death, increases persistence in vivo, and lead to a vastly improved tumor control upon ACT.